Identification of UBE3A Protein in CSF and Extracellular Space of the Hippocampus Suggest a Potential Novel Function in Synaptic Plasticity.
UBE3A protein floats outside brain cells in normal rats but disappears in Angelman rats, pointing to a fresh biomarker route.
01Research in Context
What this study did
Scientists checked rat brain fluid for UBE3A protein. They sampled cerebro-spinal fluid and hippocampal fluid.
Normal rats had the protein. Angelman rats had none. The work used lab tools, not behavior tests.
What they found
UBE3A leaks outside brain cells in healthy rats. It vanishes in Angelman rats.
This hints the protein may act like a message between cells, not just inside them.
How this fits with other research
da Silva Montenegro et al. (2020) pooled 20 000 autism cases and still flagged the 15q region that holds UBE3A. The new rat data give that region a fresh twist: the protein itself can leave the cell.
Ceylan et al. (2021) and Şimşek et al. (2021) both found blood proteins that differ in kids with ASD. They looked at serum; Andie looked at CSF. Together they widen the hunt for easy-to-collect biomarkers.
Niego et al. (2021) showed blood gene patterns can split autism from Williams syndrome. Andie’s CSF protein loss shows fluid markers can also separate Angelman from typical brains.
Why it matters
You now have a possible fluid marker for Angelman syndrome. No extra brain scan or gene lab needed—just CSF. If human studies repeat the finding, you could track drug effects or catch the syndrome sooner. Watch for future kits that test UBE3A in spinal fluid or maybe even blood.
Want CEUs on This Topic?
The ABA Clubhouse has 60+ free CEUs — live every Wednesday. Ethics, supervision & clinical topics.
Join Free →Flag any Angelman case for future CSF UBE3A testing if the neurologist orders a work-up—ask to see the result.
02At a glance
03Original abstract
Disruptions to the maternally inherited allele UBE3A, encoding for an E3 ubiquitin ligase, leads to the manifestation of Angelman Syndrome (AS). While this disorder is rare, the symptoms are severe and lifelong including but not limited to: intractable seizures, abnormal EEG's, ataxic gait, lack of speech, and most notably an abnormally happy demeanor with easily provoked laughter. Currently, little is known about the neurophysiological underpinnings of UBE3A leading to such globally severe phenotypes. Utilizing the newest AS rat model, comprised of a full UBE3A deletion, we aimed to elucidate novel mechanistic actions and potential therapeutic targets. This report demonstrates for the first time that catalytically active UBE3A protein is detectable within cerebrospinal fluid (CSF) of wild type rats but distinctly absent in AS rat CSF. Microdialysis within the rat hippocampus also showed that UBE3A protein is located in the interstitial fluid of wild type rat brains but absent in AS animals. This protein maintains catalytic activity and appears to be regulated in a dynamic activity-dependent manner. LAY SUMMARY: Angelman syndrome (AS) is a rare genetic disorder caused by the loss of the UBE3A gene within the central nervous system. Although we have identified the gene responsible for AS, we still have a long way to go to fully understand its function in vivo. Here we report that UBE3A is present within normal cerebrospinal fluid (CSF) but distinctly absent in AS CSF. Furthermore, we demonstrate that UBE3A is secreted and that this may occur in a dynamic activity-dependent fashion. Extracellular UBE3A maintained its ubiquitinating activity, thus suggesting that UBE3A may have a novel role outside of neurons. Autism Res 2021, 14: 645-655. © 2021 International Society for Autism Research and Wiley Periodicals LLC.
Autism research : official journal of the International Society for Autism Research, 2021 · doi:10.1002/aur.2475